Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses

Research output: Contribution to journalResearch articleContributed

Contributors

  • Solve-RD DITF-GENTURIS - (Author)
  • Institute of Clinical Genetics
  • National Center for Tumor Diseases Dresden
  • Autonomous University of Barcelona
  • Radboud University Medical Center
  • Children's Hospital of Eastern Ontario (CHEO)
  • Ghent University Hospital
  • University of Bonn Medical Center
  • University of Tübingen
  • European Molecular Biology Laboratory (EMBL) Hinxton
  • Antwerp University Hospital (UZA)
  • University of Siena
  • University of Cambridge
  • Manchester University NHS Foundation Trust
  • Sorbonne Université
  • Jackson Laboratory
  • Assistance publique – Hôpitaux de Paris
  • Dijon University Hospital (CHU Dijon Bourgogne)
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
  • University College London
  • University of Porto
  • German Center for Neurodegenerative Diseases (DZNE) - Partner Site Tübingen
  • University Medical Center Groningen
  • University of Helsinki
  • Vincent van Gogh Institute for Psychiatry
  • University Hospital of Bordeaux
  • University of Ottawa
  • Instituto de Salud Carlos III
  • Vall d'Hebron Research Institute (VHIR)
  • University Medical Centre Ljubljana
  • Alexandria University
  • Great Ormond Street Hospital for Children NHS Trust
  • Telethon Institute of Genetics and Medicine

Abstract

Genetic diagnosis of rare diseases requires accurate identification and interpretation of genomic variants. Clinical and molecular scientists from 37 expert centers across Europe created the Solve-Rare Diseases Consortium (Solve-RD) resource, encompassing clinical, pedigree and genomic rare-disease data (94.5% exomes, 5.5% genomes), and performed systematic reanalysis for 6,447 individuals (3,592 male, 2,855 female) with previously undiagnosed rare diseases from 6,004 families. We established a collaborative, two-level expert review infrastructure that allowed a genetic diagnosis in 506 (8.4%) families. Of 552 disease-causing variants identified, 464 (84.1%) were single-nucleotide variants or short insertions/deletions. These variants were either located in recently published novel disease genes (n = 67), recently reclassified in ClinVar (n = 187) or reclassified by consensus expert decision within Solve-RD (n = 210). Bespoke bioinformatics analyses identified the remaining 15.9% of causative variants (n = 88). Ad hoc expert review, parallel to the systematic reanalysis, diagnosed 249 (4.1%) additional families for an overall diagnostic yield of 12.6%. The infrastructure and collaborative networks set up by Solve-RD can serve as a blueprint for future further scalable international efforts. The resource is open to the global rare-disease community, allowing phenotype, variant and gene queries, as well as genome-wide discoveries.

Details

Original languageEnglish
Article number206
Pages (from-to)478-489
Number of pages12
JournalNature medicine
Volume31
Issue number2
Publication statusPublished - Feb 2025
Peer-reviewedNo

External IDs

PubMedCentral PMC11835725
Scopus 85217578337

Keywords

Sustainable Development Goals

Keywords

  • Humans, Rare Diseases/genetics, Europe, Male, Genomics/methods, Female, Pedigree, Databases, Genetic, Computational Biology/methods, Genome, Human/genetics, Exome/genetics